Cosmo N.V. (SWX:CMHC)

Market Cap	978.14M +10.6%
Revenue (ttm)	94.79M -43.7%
Net Income	-5.86M
EPS	-0.36
Shares Out	17.19M
PE Ratio	n/a
Forward PE	920.36
Dividend	1.97 (3.45%)
Ex-Dividend Date	Apr 24, 2026

Volume	32,567
Open	58.00
Previous Close	57.10
Day's Range	56.50 - 58.40
52-Week Range	55.20 - 129.40
Beta	1.48
Analysts	Strong Buy
Price Target	123.36 (+116.8%)
Earnings Date	n/a

About Cosmo

Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral ...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 365
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: CMHC

Financial Performance

Financial numbers in EUR

Analyst Summary

According to 5 analysts, the average rating for CMHC stock is "Strong Buy." The 12-month stock price target is CHF 123.36, which is an increase of 116.80% from the latest price.

Price Target

CHF 123.36

(116.80% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 18, 2026

Data Sources Report a data error